Parameter | n (%) |
---|---|
Gender | |
Male | 59 (57.3%) |
Female | 44 (42.7%) |
Mean age | 36 years (range: 13–85) |
Age ≥ 45 years | 28 (27%) |
Ann Arbor Stage | |
I | 9 (8.7%) |
II | 48 (46.6%) |
III | 26 (25.2%) |
IV | 20 (19.4%) |
IPS | |
< 3 | 83 (80.6%) |
≥ 3 | 20 (19.4%) |
Radiotherapy | |
No | 21 (22.6%) |
Yes | 72 (77.4%) |
Chemotherapy | |
ABVD | 34 (33%) |
ABVD + rituximab | 2 (1.94%) |
CVPP/ABDIC | 20 (19.4%) |
MOPP/ABVD | 3 (2.9%) |
NOVP | 44 (42.7%) |
CHL Histologic Subtype: | |
Nodular sclerosis | 75 (72.8%) |
Mixed cellularity | 22 (21.3%) |
Lymphocyte rich | 3 (2.9%) |
Lymphocyte depleted | 3 (2.9%) |